Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.
about
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerThe benign mimickers of prostatic acinar adenocarcinomaRadium-223 dichloride in clinical practice: a review.Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancerBicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients.Management of prostate cancer in port harcourt, Nigeria: changing patterns.Age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis.Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.Updated trends in imaging use in men diagnosed with prostate cancer.Age-related increase in IL-17 activates pro-inflammatory signaling in prostate cells.Role of immunohistochemistry and apoptosis as investigative tools in assessing the prognosis of patients with prostate tumours.Prostatic adenocarcinoma presenting with metastases to the testis and epididymis: A case report.Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphyMechanism and Function of Angiogenin in Prostate Cancer.Prostate cancer: the need for biomarkers and new therapeutic targets.Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer.Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancerPrior-cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate-cancer-specific and all-cause mortality.Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).Imaging and evaluation of patients with high-risk prostate cancer.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Can glycoprofiling be helpful in detecting prostate cancer?Evaluation of PSF1 as a prognostic biomarker for prostate cancer.On-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA.Prostate cancer outcomes for men who present with symptoms at diagnosis.Thiazolidenediones induce tumour-cell apoptosis through the Akt-GSK3β pathway.Digital rectal examination (DRE) does not influence total serum levels of prostate specific antigen (tPSA), in individuals without prostate pathology.Geographical variation in incidence of prostate cancer in Sweden.Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.Prostate carcinoma, presenting with a solitary osteolytic bone lesion to the right hip.Nanomaterial-based biosensors for detection of prostate specific antigen.Development of a computational simulation tool to design a protocol for treating prostate tumours using transurethral laser photothermal therapy.Identification of potential key genes and high-frequency mutant genes in prostate cancer by using RNA-Seq data.Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis.
P2860
Q26752785-52C3EE34-3EE9-4301-B9D1-45E1819E973CQ26752929-B3BD91F9-FAE2-41D8-8C1A-248B857BF12FQ30251496-D6CA8AA3-505B-486A-930B-56534C0E8D15Q33464875-62BF9123-A0D9-4464-9DF9-1A2F41932A4AQ34394508-94369C11-C83A-47D2-80D5-6CF401150C6EQ34550344-E994F115-81D9-47D0-AF83-5E1B561DD98AQ34555654-2D829ED9-DE9B-4D4E-B858-F1226C2CD28CQ34637326-0758D899-E10D-42E6-B642-2E3E1B122BE3Q34644401-C9D25001-ED25-4B6A-A058-FD7823A5A75EQ34704662-B7C5DEB7-A497-4FAE-947F-B1DC9CF09301Q35538312-8E26CEA6-D525-4721-8112-0ECBE2861D65Q36244240-DD074BB6-D161-437E-AF2E-8AC4B84685C9Q36502810-9F628476-068D-4AC2-85B5-46C22B6B9BFBQ36879606-BAD4A8A2-CF99-4DDF-9C82-C683DF9FA9C4Q36888285-F3314290-8BEE-4D93-B2A9-34A56EACC3CCQ37476043-7563593F-65A6-4D50-A56B-9EC4268621FAQ37538185-6EA873DC-D896-4F1E-82AC-114D980B942BQ37542029-EF1498C8-B74F-4C80-B984-8221FFA433A3Q37593583-45DF63F6-A302-4F54-8C4C-3AEEECE41CA4Q37706084-3AF2E912-DB40-4D6E-A44D-BB39FA87E32BQ38382252-7BA7B5DD-60A3-4F19-BE25-1E22546BCB37Q38593365-65A44BD3-D17D-446F-BCF9-F87659BBE6B2Q38611187-A30DDE67-4403-41B2-B894-255EEACFF172Q38766102-A31B9340-2705-49FD-B973-5AF8A783E8D3Q38852467-26B37FDB-194A-4851-95FC-978541DFF807Q38939897-C131BC33-EDB7-44D0-B9C7-68D6EFFDCECBQ39378788-3F2EA4AC-685B-4283-9F61-7B244785AA26Q39526823-49FB3740-4412-4119-BCC3-52B80FF1CEF9Q39575339-344D172E-69F9-43DF-A77E-8781DE9209A4Q39709507-2D2E1D13-FC21-4DDD-990A-8B8C4CC81D2FQ39734785-37E3C927-1030-4310-B1E0-3BF95A287D0BQ39975132-65288D4F-E917-4BAD-B77F-D071D4C28E77Q42082921-339CBA37-992E-415B-B22A-452084F4D0EBQ50131303-215B624E-C591-4D24-AB80-8440ED2ABFA3Q51034868-1CDDD412-E9F2-4D1F-874E-44EF2D1D0003Q52608493-7D964DCF-93D3-4F2A-9533-98D273418C6AQ55714340-9333A967-7319-4D0E-802D-36D45B10713B
P2860
Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Prostate carcinoma presentatio ...... the National Cancer Data Base.
@ast
Prostate carcinoma presentatio ...... the National Cancer Data Base.
@en
type
label
Prostate carcinoma presentatio ...... the National Cancer Data Base.
@ast
Prostate carcinoma presentatio ...... the National Cancer Data Base.
@en
prefLabel
Prostate carcinoma presentatio ...... the National Cancer Data Base.
@ast
Prostate carcinoma presentatio ...... the National Cancer Data Base.
@en
P2093
P356
P1433
P1476
Prostate carcinoma presentatio ...... the National Cancer Data Base.
@en
P2093
Andrew Stewart
David C Miller
James E Montie
John T Wei
Khaled S Hafez
P304
P356
10.1002/CNCR.11635
P407
P577
2003-09-01T00:00:00Z